psilocybin treatment Search Results


psilocybin treatment  (Compass Pathways Ltd)
90
Compass Pathways Ltd psilocybin treatment
Mechanism of action of classic serotonergic drugs. 5-HT serotonin receptors are densely located in areas of the brain that are responsible for mediation of mood and anxiety disorders such as the pre-frontal cortex [ , ]. Classic serotonergic psychedelic drugs such as LSD, DMT, 5-MeO-DMT, mescaline, <t>psilocybin</t> and MDMA all have an affinity for serotonergic 5-HT receptors which may mediate the psychotomimetic and pharmacological effects of psychedelic drugs. LSD may also interact with dopamine D2 receptors and trace-amine associated receptors (TAARs) to produce psychotomimetic and pharmacological effects . DMT also interacts agonistically with the sigma-1 receptor (Sig1R) [ , ] and trace-amine associated receptors (TAARs) to produce anti-inflammatory and anti-oxidant effects . In pre-clinical animal models, trace-amine associated receptors such as TAAR1 have been identified as a novel target for metabolic disorders, drug addiction, neurological and psychiatric diseases such as depression and schizophrenia [ , , , ].
Psilocybin Treatment, supplied by Compass Pathways Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/psilocybin treatment/product/Compass Pathways Ltd
Average 90 stars, based on 1 article reviews
psilocybin treatment - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
psilocybin treatment  (Usona Institute Inc)
90
Usona Institute Inc psilocybin treatment
An overview of the characteristics of <t>psilocybin.</t> The diagram includes the chemical structures of psilocybin and its metabolite. The bold lines indicate similarities in the chemical structure between this psychedelic and serotonin. In addition, the enzymes and major organs involved in the metabolism and excretion of psilocybin are indicated. The mechanism of action represents the targets of the psychedelic, both the region of the brain affected by the psychedelic and the receptors with which it interacts (pink circle for agonist). 5HT—serotonin receptors (2Ar, 1Ar, 2Cr, – subtypes). IP3, inositol-3-phosphate; cAMP, cyclic adenosine monophosphate.
Psilocybin Treatment, supplied by Usona Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/psilocybin treatment/product/Usona Institute Inc
Average 90 stars, based on 1 article reviews
psilocybin treatment - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
a trial of psilocybin therapy for treatment-resistant depression  (Compass Pathways Ltd)
90
Compass Pathways Ltd a trial of psilocybin therapy for treatment-resistant depression
An overview of the characteristics of <t>psilocybin.</t> The diagram includes the chemical structures of psilocybin and its metabolite. The bold lines indicate similarities in the chemical structure between this psychedelic and serotonin. In addition, the enzymes and major organs involved in the metabolism and excretion of psilocybin are indicated. The mechanism of action represents the targets of the psychedelic, both the region of the brain affected by the psychedelic and the receptors with which it interacts (pink circle for agonist). 5HT—serotonin receptors (2Ar, 1Ar, 2Cr, – subtypes). IP3, inositol-3-phosphate; cAMP, cyclic adenosine monophosphate.
A Trial Of Psilocybin Therapy For Treatment Resistant Depression, supplied by Compass Pathways Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a trial of psilocybin therapy for treatment-resistant depression/product/Compass Pathways Ltd
Average 90 stars, based on 1 article reviews
a trial of psilocybin therapy for treatment-resistant depression - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
psilocybin treatments for major depressive disorder (mdd)  (Compass Pathways Ltd)
90
Compass Pathways Ltd psilocybin treatments for major depressive disorder (mdd)
An overview of the characteristics of <t>psilocybin.</t> The diagram includes the chemical structures of psilocybin and its metabolite. The bold lines indicate similarities in the chemical structure between this psychedelic and serotonin. In addition, the enzymes and major organs involved in the metabolism and excretion of psilocybin are indicated. The mechanism of action represents the targets of the psychedelic, both the region of the brain affected by the psychedelic and the receptors with which it interacts (pink circle for agonist). 5HT—serotonin receptors (2Ar, 1Ar, 2Cr, – subtypes). IP3, inositol-3-phosphate; cAMP, cyclic adenosine monophosphate.
Psilocybin Treatments For Major Depressive Disorder (Mdd), supplied by Compass Pathways Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/psilocybin treatments for major depressive disorder (mdd)/product/Compass Pathways Ltd
Average 90 stars, based on 1 article reviews
psilocybin treatments for major depressive disorder (mdd) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
using psilocybin to identify a candidate therapeutic agent for treatment of a cognitive deficit.  (Galenea Inc)
90
Galenea Inc using psilocybin to identify a candidate therapeutic agent for treatment of a cognitive deficit.
An overview of the characteristics of <t>psilocybin.</t> The diagram includes the chemical structures of psilocybin and its metabolite. The bold lines indicate similarities in the chemical structure between this psychedelic and serotonin. In addition, the enzymes and major organs involved in the metabolism and excretion of psilocybin are indicated. The mechanism of action represents the targets of the psychedelic, both the region of the brain affected by the psychedelic and the receptors with which it interacts (pink circle for agonist). 5HT—serotonin receptors (2Ar, 1Ar, 2Cr, – subtypes). IP3, inositol-3-phosphate; cAMP, cyclic adenosine monophosphate.
Using Psilocybin To Identify A Candidate Therapeutic Agent For Treatment Of A Cognitive Deficit., supplied by Galenea Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/using psilocybin to identify a candidate therapeutic agent for treatment of a cognitive deficit./product/Galenea Inc
Average 90 stars, based on 1 article reviews
using psilocybin to identify a candidate therapeutic agent for treatment of a cognitive deficit. - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
clinical trials assessing the use of psilocybin in an treatment  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare clinical trials assessing the use of psilocybin in an treatment
Novel treatments to target anorexia nervosa core and associated behaviors.
Clinical Trials Assessing The Use Of Psilocybin In An Treatment, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/clinical trials assessing the use of psilocybin in an treatment/product/Johns Hopkins HealthCare
Average 90 stars, based on 1 article reviews
clinical trials assessing the use of psilocybin in an treatment - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Mechanism of action of classic serotonergic drugs. 5-HT serotonin receptors are densely located in areas of the brain that are responsible for mediation of mood and anxiety disorders such as the pre-frontal cortex [ , ]. Classic serotonergic psychedelic drugs such as LSD, DMT, 5-MeO-DMT, mescaline, psilocybin and MDMA all have an affinity for serotonergic 5-HT receptors which may mediate the psychotomimetic and pharmacological effects of psychedelic drugs. LSD may also interact with dopamine D2 receptors and trace-amine associated receptors (TAARs) to produce psychotomimetic and pharmacological effects . DMT also interacts agonistically with the sigma-1 receptor (Sig1R) [ , ] and trace-amine associated receptors (TAARs) to produce anti-inflammatory and anti-oxidant effects . In pre-clinical animal models, trace-amine associated receptors such as TAAR1 have been identified as a novel target for metabolic disorders, drug addiction, neurological and psychiatric diseases such as depression and schizophrenia [ , , , ].

Journal: Molecules

Article Title: Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders

doi: 10.3390/molecules27082520

Figure Lengend Snippet: Mechanism of action of classic serotonergic drugs. 5-HT serotonin receptors are densely located in areas of the brain that are responsible for mediation of mood and anxiety disorders such as the pre-frontal cortex [ , ]. Classic serotonergic psychedelic drugs such as LSD, DMT, 5-MeO-DMT, mescaline, psilocybin and MDMA all have an affinity for serotonergic 5-HT receptors which may mediate the psychotomimetic and pharmacological effects of psychedelic drugs. LSD may also interact with dopamine D2 receptors and trace-amine associated receptors (TAARs) to produce psychotomimetic and pharmacological effects . DMT also interacts agonistically with the sigma-1 receptor (Sig1R) [ , ] and trace-amine associated receptors (TAARs) to produce anti-inflammatory and anti-oxidant effects . In pre-clinical animal models, trace-amine associated receptors such as TAAR1 have been identified as a novel target for metabolic disorders, drug addiction, neurological and psychiatric diseases such as depression and schizophrenia [ , , , ].

Article Snippet: In 2018 Compass Pathways Ltd. (London, UK) received FDA approval of “breakthrough therapy” status for a psilocybin treatment they developed for treatment-resistant depression [ ].

Techniques:

An overview of the characteristics of psilocybin. The diagram includes the chemical structures of psilocybin and its metabolite. The bold lines indicate similarities in the chemical structure between this psychedelic and serotonin. In addition, the enzymes and major organs involved in the metabolism and excretion of psilocybin are indicated. The mechanism of action represents the targets of the psychedelic, both the region of the brain affected by the psychedelic and the receptors with which it interacts (pink circle for agonist). 5HT—serotonin receptors (2Ar, 1Ar, 2Cr, – subtypes). IP3, inositol-3-phosphate; cAMP, cyclic adenosine monophosphate.

Journal: Frontiers in Pharmacology

Article Title: Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders

doi: 10.3389/fphar.2022.927984

Figure Lengend Snippet: An overview of the characteristics of psilocybin. The diagram includes the chemical structures of psilocybin and its metabolite. The bold lines indicate similarities in the chemical structure between this psychedelic and serotonin. In addition, the enzymes and major organs involved in the metabolism and excretion of psilocybin are indicated. The mechanism of action represents the targets of the psychedelic, both the region of the brain affected by the psychedelic and the receptors with which it interacts (pink circle for agonist). 5HT—serotonin receptors (2Ar, 1Ar, 2Cr, – subtypes). IP3, inositol-3-phosphate; cAMP, cyclic adenosine monophosphate.

Article Snippet: Subsequently, the FDA also designated “breakthrough therapy” status to psilocybin treatment for MDD in trials financially supported by the Usona Institute ( ).

Techniques:

The common adverse effects related to psilocybin exposure.

Journal: Frontiers in Pharmacology

Article Title: Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders

doi: 10.3389/fphar.2022.927984

Figure Lengend Snippet: The common adverse effects related to psilocybin exposure.

Article Snippet: Subsequently, the FDA also designated “breakthrough therapy” status to psilocybin treatment for MDD in trials financially supported by the Usona Institute ( ).

Techniques:

An overview of the characteristics of DMT. The diagram includes the chemical structures of DMT and its metabolite. The bold lines indicate similarities in the chemical structure between this psychedelic and serotonin. In addition, the enzymes and major organs involved in the metabolism and excretion of psilocybin are indicated. The mechanism of action represents the targets of the psychedelic, both the region of the brain affected by the psychedelic and the receptors with which it interacts (pink circle for agonist). 5HT—serotonin receptors (2Ar, 2Cr,—subtypes), sigma 1 receptor. MAOI, monoamine oxidase I; IP3, inositol-3-phosphate; ER, endoplasmic reticulum.

Journal: Frontiers in Pharmacology

Article Title: Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders

doi: 10.3389/fphar.2022.927984

Figure Lengend Snippet: An overview of the characteristics of DMT. The diagram includes the chemical structures of DMT and its metabolite. The bold lines indicate similarities in the chemical structure between this psychedelic and serotonin. In addition, the enzymes and major organs involved in the metabolism and excretion of psilocybin are indicated. The mechanism of action represents the targets of the psychedelic, both the region of the brain affected by the psychedelic and the receptors with which it interacts (pink circle for agonist). 5HT—serotonin receptors (2Ar, 2Cr,—subtypes), sigma 1 receptor. MAOI, monoamine oxidase I; IP3, inositol-3-phosphate; ER, endoplasmic reticulum.

Article Snippet: Subsequently, the FDA also designated “breakthrough therapy” status to psilocybin treatment for MDD in trials financially supported by the Usona Institute ( ).

Techniques:

Novel treatments to target anorexia nervosa core and associated behaviors.

Journal: Expert opinion on pharmacotherapy

Article Title: Pharmacotherapeutic strategies for the treatment of anorexia nervosa – novel targets to break a vicious cycle

doi: 10.1080/14656566.2024.2424316

Figure Lengend Snippet: Novel treatments to target anorexia nervosa core and associated behaviors.

Article Snippet: Of note, Johns Hopkins University ( NCT04052568 ) and Imperial College London ( NCT04505189 ) have completed clinical trials assessing the use of psilocybin in AN treatment.

Techniques: Drug discovery, Activity Assay, Concentration Assay